A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引:5
作者
Abali, Huseyin
Yalcin, Suayib
Onal, Huseyin Cem
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye
Mertsoylu, Huseyin
Artac, Mehmet
Camci, Celalettin
Karabulut, Bulent
Basal, Fatma Bugdayci
Budakoglu, Burcin
Sendur, Mehmet Ali Nahit
Goktas, Burce
Ozdener, Fatih
Calisgan, Arzu
机构
[1] Acibadem Univ, Adana, Turkey
[2] Hacettepe Univ, Ankara, Turkey
[3] Baskent Univ, Radiat Oncol, Adana, Turkey
[4] Marmara Univ, Istanbul, Turkey
[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey
[6] Ankara Numune Training & Res Hosp, Ankara, Turkey
[7] Baskent Univ, Adana, Turkey
[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey
[9] Gaziantep Univ, Gaziantep, Turkey
[10] Ege Univ, Izmir, Turkey
[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey
[12] Roche Pharmaceut, Istanbul, Turkey
[13] Medstats Consulting, Istanbul, Turkey
关键词
D O I
10.1200/jco.2016.34.4_suppl.tps182
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
TPS182
引用
收藏
页数:1
相关论文
empty
未找到相关数据